Legato Capital Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Legato Capital Management LLC

  • $718 Million
  • Q4 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024
BUY
$55.39 - $72.47 $319,046 - $417,427
5,760 Added 141.7%
9,825 $577,000
Q4 2023

Jan 16, 2024
SELL
$37.14 - $64.82 $89,693 - $156,540
-2,415 Reduced 37.27%
4,065 $243,000
Q3 2023

Oct 12, 2023
BUY
$23.65 - $89.22 $153,252 - $578,145
6,480 New
6,480 $246,000
Q2 2023

Aug 17, 2023
BUY
$76.68 - $93.31 $145,768 - $177,382
1,901 Added 27.31%
8,862 $807,000
Q4 2022

Feb 01, 2023
BUY
$43.24 - $61.04 $300,993 - $424,899
6,961 New
6,961 $359,000

Others Institutions Holding APLS

# of Institutions
301
Shares Held
111M
Call Options Held
2.63M
Put Options Held
845K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.67B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Legato Capital Management LLC Portfolio

Follow Legato Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legato Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Legato Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email